My name is Dr. Oliver Distler and I am serving on the medical advisory board of ISN. I am heading the scleroderma outpatient clinic at the University of Zurich, Switzerland.
Next to my medical duties, my research group is working in the field of molecular biology to identify molecular targets for therapy in systemic sclerosis.
How did I get in contact with scleroderma as a medical speciality? This was more than twelve years ago, when the German scleroderma self help group provided research grants for young medical doctors to conduct research in scleroderma. Ever since then I have continued my research on scleroderma.
Department of Rheumatology
University Hospital Zurich
Email: [email protected]
Scleroderma Experts at the University Hospital Zurich. These experts diagnose and treat systemic sclerosis in adults. Posted 07/13/12.
MicroRNA-29, a Key Regulator of Collagen Expression in Systemic Sclerosis. In systemic sclerosis, miR-29a directly regulates collagen expression at the post-transcriptional level, which is a novel aspect of the complex regulatory network of fibrosis. Arthritis and Rheumatism, Vol. 62, No. 6, June 2010, pp 1733-1743. (Also see: Scleroderma Treatments)
Dr. Oliver Distler: ISN Medical Advisory Board. I am heading the scleroderma outpatient clinic at the University of Zurich, Switzerland. Next to my medical duties, my research group is working in the field of molecular biology to identify molecular targets for therapy in systemic sclerosis. Posted 03-30-08.
Cells of the synovium in rheumatoid arthritis. Synovial fibroblasts. A body of evidence has accumulated illustrating that rheumatoid arthritis synovial fibroblasts are active drivers of joint destruction in rheumatoid arthritis. Ulf Müller-Ladner, Caroline Ospelt, Steffen Gay, Oliver Distler, and Thomas Pap, Arthritis Research & Therapy 2007, 9(6): 223. (Also see Rheumatoid Arthritis and Prof. Ulf Müller-Ladner, MD: ISN Medical Advisory Board)
SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to: